Kropec A, Lemmen S, Wursthorn M, Daschner F D
Institute of Environmental Medicine, Freiburg, Germany.
Infection. 1994 Jul-Aug;22(4):306-8. doi: 10.1007/BF01739926.
The in vitro activity of meropenem, a new carbapenem, and the combination effect with netilmicin, tobramycin, gentamicin, and teicoplanin against Pseudomonas spp. and enterococci was studied. Meropenem showed very good in vitro activity against Pseudomonas aeruginosa (MIC90 2 mg/l) and good to moderate activity against Pseudomonas putida (MIC90 4 mg/l) and Enterococcus faecalis (MIC90 8 mg/l). Aminoglycosides were highly active against P. putida (MIC90 0.5 mg/l), but showed only moderate activity against P. aeruginosa. The synergistic effect of meropenem was shown in combination with teicoplanin against E. faecalis (40%). No Pseudomonas strains were inhibited by the synergistic effect of meropenem with aminoglycosides. No antagonism occurred with any of the combinations.
研究了新型碳青霉烯类药物美罗培南以及它与奈替米星、妥布霉素、庆大霉素和替考拉宁联合使用对假单胞菌属和肠球菌的体外活性。美罗培南对铜绿假单胞菌显示出非常好的体外活性(MIC90为2mg/l),对恶臭假单胞菌(MIC90为4mg/l)和粪肠球菌(MIC90为8mg/l)显示出良好至中等活性。氨基糖苷类药物对恶臭假单胞菌具有高活性(MIC90为0.5mg/l),但对铜绿假单胞菌仅显示出中等活性。美罗培南与替考拉宁联合使用对粪肠球菌显示出协同作用(40%)。美罗培南与氨基糖苷类药物联合使用未对任何假单胞菌菌株产生协同抑制作用。所有联合使用均未出现拮抗作用。